FR2844520B1 - Utilisation d'un anticorps induisant la secretion de cytokines en therapie - Google Patents

Utilisation d'un anticorps induisant la secretion de cytokines en therapie

Info

Publication number
FR2844520B1
FR2844520B1 FR0211415A FR0211415A FR2844520B1 FR 2844520 B1 FR2844520 B1 FR 2844520B1 FR 0211415 A FR0211415 A FR 0211415A FR 0211415 A FR0211415 A FR 0211415A FR 2844520 B1 FR2844520 B1 FR 2844520B1
Authority
FR
France
Prior art keywords
cytokines
secretion
therapy
antibody inducing
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0211415A
Other languages
English (en)
Other versions
FR2844520A1 (fr
Inventor
Romeuf Christophe De
Christine Gaucher
Arnaud Glacet
Frederic Dhainaut
Dominique Bourel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR0211415A priority Critical patent/FR2844520B1/fr
Priority to FR0307067A priority patent/FR2844513B1/fr
Priority to FR0307066A priority patent/FR2844455B1/fr
Priority to PCT/FR2003/002715 priority patent/WO2004024768A2/fr
Priority to PCT/FR2003/002713 priority patent/WO2004029092A2/fr
Priority to CA002498787A priority patent/CA2498787A1/fr
Priority to JP2004535611A priority patent/JP4368800B2/ja
Priority to AT03773780T priority patent/ATE511654T1/de
Priority to EP09152731A priority patent/EP2092939A3/fr
Priority to EP15182965.2A priority patent/EP3001198A1/fr
Priority to US10/527,664 priority patent/US20060127392A1/en
Priority to JP2004539110A priority patent/JP2006504700A/ja
Priority to ES03773780T priority patent/ES2362652T3/es
Priority to EP03775438A priority patent/EP1545614A2/fr
Priority to PCT/FR2003/002714 priority patent/WO2004028564A2/fr
Priority to AU2003282160A priority patent/AU2003282160A1/en
Priority to DE60334700T priority patent/DE60334700D1/de
Priority to CA2498315A priority patent/CA2498315C/fr
Priority to US10/527,665 priority patent/US7595165B2/en
Priority to CA2498383A priority patent/CA2498383C/fr
Priority to DK03773780.6T priority patent/DK1537419T3/da
Priority to AU2003283469A priority patent/AU2003283469C1/en
Priority to AU2003282161A priority patent/AU2003282161B2/en
Priority to US10/527,666 priority patent/US20050271652A1/en
Priority to EP03773780A priority patent/EP1537419B1/fr
Priority to AT03773779T priority patent/ATE486094T1/de
Priority to JP2004539109A priority patent/JP2006516951A/ja
Priority to EP03773779A priority patent/EP1537147B9/fr
Publication of FR2844520A1 publication Critical patent/FR2844520A1/fr
Priority to IL167381A priority patent/IL167381A/en
Priority to IL167385A priority patent/IL167385A/en
Application granted granted Critical
Publication of FR2844520B1 publication Critical patent/FR2844520B1/fr
Priority to US12/234,609 priority patent/US20090081216A1/en
Priority to JP2009190989A priority patent/JP5951923B2/ja
Priority to US12/585,900 priority patent/US20100323368A1/en
Priority to US12/576,202 priority patent/US20100145026A1/en
Priority to IL230101A priority patent/IL230101A/en
Priority to JP2013272030A priority patent/JP6238743B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR0211415A 2002-09-13 2002-09-13 Utilisation d'un anticorps induisant la secretion de cytokines en therapie Expired - Lifetime FR2844520B1 (fr)

Priority Applications (36)

Application Number Priority Date Filing Date Title
FR0211415A FR2844520B1 (fr) 2002-09-13 2002-09-13 Utilisation d'un anticorps induisant la secretion de cytokines en therapie
FR0307066A FR2844455B1 (fr) 2002-09-13 2003-06-12 Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR0307067A FR2844513B1 (fr) 2002-09-13 2003-06-12 Anticorps pour adcc et induisant la production de cytokines.
US10/527,665 US7595165B2 (en) 2002-09-13 2003-09-15 Method of measuring activation of effector cells
CA002498787A CA2498787A1 (fr) 2002-09-13 2003-09-15 Anticorps pour adcc et induisant la production de cytokines
JP2004535611A JP4368800B2 (ja) 2002-09-13 2003-09-15 サイトカイン産生誘導抗体
AT03773780T ATE511654T1 (de) 2002-09-13 2003-09-15 Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern
EP09152731A EP2092939A3 (fr) 2002-09-13 2003-09-15 Utilisation thérapeutique d'anticorps induisant la production de cytokines
EP15182965.2A EP3001198A1 (fr) 2002-09-13 2003-09-15 Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US10/527,664 US20060127392A1 (en) 2002-09-13 2003-09-15 Antibody for adcc and inducing cytokine production
AU2003283469A AU2003283469C1 (en) 2002-09-13 2003-09-15 Treatment of pathologies which escape the immune response, using optimised antibodies
ES03773780T ES2362652T3 (es) 2002-09-13 2003-09-15 Procedimiento de evaluación de la eficacia adcc mediada por el cd16 de anticuerpos monoclonales o policlonales.
EP03775438A EP1545614A2 (fr) 2002-09-13 2003-09-15 Traitement des pathologies echappant a la reponse immune par des anticorps optimises
PCT/FR2003/002714 WO2004028564A2 (fr) 2002-09-13 2003-09-15 Traitement des pathologies echappant a la reponse immune par des anticorps optimises
AU2003282160A AU2003282160A1 (en) 2002-09-13 2003-09-15 Antibody for adcc and inducing cytokine production
DE60334700T DE60334700D1 (de) 2002-09-13 2003-09-15 Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren
CA2498315A CA2498315C (fr) 2002-09-13 2003-09-15 Anticorps induisant la production de cytokines
PCT/FR2003/002713 WO2004029092A2 (fr) 2002-09-13 2003-09-15 Anticorps pour adcc et induisant la production de cytokines.
PCT/FR2003/002715 WO2004024768A2 (fr) 2002-09-13 2003-09-15 Anticorps induisant la production de cytokines
DK03773780.6T DK1537419T3 (da) 2002-09-13 2003-09-15 Test for CD16-medieret ADCC effektivitet af monoklonale og polyklonale antistoffer
JP2004539110A JP2006504700A (ja) 2002-09-13 2003-09-15 最適化抗体を用いた、免疫応答を逃れる病態の治療法
AU2003282161A AU2003282161B2 (en) 2002-09-13 2003-09-15 Cytokine production-inducing antibody
CA2498383A CA2498383C (fr) 2002-09-13 2003-09-15 Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP03773780A EP1537419B1 (fr) 2002-09-13 2003-09-15 Procédé d'évaluation de l'efficacité ADCC médiée par le CD16 d'anticorps monoclonaux ou polyclonaux
AT03773779T ATE486094T1 (de) 2002-09-13 2003-09-15 Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren
JP2004539109A JP2006516951A (ja) 2002-09-13 2003-09-15 Ａｄｃｃおよびサイトカイン産生の誘導のための抗体
EP03773779A EP1537147B9 (fr) 2002-09-13 2003-09-15 Anticorps anti hla-dr ayant une adcc augmentée et induisant la production de cytokines.
US10/527,666 US20050271652A1 (en) 2002-09-13 2003-09-15 Treatment of pathologies which escape the immune response, using optimised antibodies
IL167381A IL167381A (en) 2002-09-13 2005-03-10 Use of an Enhanced Monoclonal Antibody to Prepare a Pharmaceutical Compound for the Treatment of Immune Response Diseases
IL167385A IL167385A (en) 2002-09-13 2005-03-10 Method for selecting a monoclonal antibody for increased antibody-dependent cellular cytotoxicity activity
US12/234,609 US20090081216A1 (en) 2002-09-13 2008-09-19 Treatment of pathologies which escape the immune response, using optimized antibodies
JP2009190989A JP5951923B2 (ja) 2002-09-13 2009-08-20 最適化抗体を用いた、免疫応答を逃れる病態の治療法
US12/585,900 US20100323368A1 (en) 2002-09-13 2009-09-28 Cytokine production-inducing antibody
US12/576,202 US20100145026A1 (en) 2002-09-13 2009-10-08 Antibody for ADCC And Inducing Cytokine Production
IL230101A IL230101A (en) 2002-09-13 2013-12-23 Use of fine antibodies to make drugs to treat pathological evasion of immune response
JP2013272030A JP6238743B2 (ja) 2002-09-13 2013-12-27 最適化抗体を用いた、免疫応答を逃れる病態の治療法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0211415A FR2844520B1 (fr) 2002-09-13 2002-09-13 Utilisation d'un anticorps induisant la secretion de cytokines en therapie

Publications (2)

Publication Number Publication Date
FR2844520A1 FR2844520A1 (fr) 2004-03-19
FR2844520B1 true FR2844520B1 (fr) 2006-06-09

Family

ID=31897390

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0211415A Expired - Lifetime FR2844520B1 (fr) 2002-09-13 2002-09-13 Utilisation d'un anticorps induisant la secretion de cytokines en therapie

Country Status (2)

Country Link
ES (1) ES2362652T3 (fr)
FR (1) FR2844520B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059540A1 (fr) * 1999-04-05 2000-10-12 Biocrystal Ltd. Trousses et procedes de titrage pour une activation par des complexes immuns contenant des antigenes shed
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d

Also Published As

Publication number Publication date
ES2362652T3 (es) 2011-07-08
FR2844520A1 (fr) 2004-03-19

Similar Documents

Publication Publication Date Title
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
HK1109867A1 (en) Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
EE200100370A (et) Teraapias kasutatavad spirofuropüridiinide uued aralküülamiinid
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
DE60221143D1 (de) Brusteinlage enthaltend hautpflegemittel
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DK1114821T3 (da) Benzopyraner og disses anvendelse som terapeutiske midler
IS6381A (is) Nýjung við notkun mótefna í bóluefni
FR2747230B1 (fr) Bouton d'arret d'urgence cadenassable
FR2844520B1 (fr) Utilisation d'un anticorps induisant la secretion de cytokines en therapie
MA27184A1 (fr) Dosage d'anticorps anti-ingap
FR2804320B1 (fr) Composition cosmetique favorisant la respiration cellulaire
EP1370651A4 (fr) 70 proteines humaines secretees
ITMI20011404A0 (it) Preparazione dietetica ed attivita' ipocolesterololemizzante
ITMI20032291A1 (it) Procedimento e dispositivo per l'approntamento di un combustibile
ITMI20010761A0 (it) Uso della proteina uk114 per il trattamento e la prevenzione dell'epatite cronica attiva
IT1296032B1 (it) Carrello semovente trasportabile con sedia amovibile standard per persone con problemi di deambulazione utilizzabile negli interni
NO20010630L (no) Krummet trapp og trappetrinn for krummet trapp
FR2837707B1 (fr) Utilisation de la 8'-hydroxydihydroergotamine pour un medicament anxiolytique
ID27282A (id) Protein c polipeptida pada manusia
ITPD20020240A1 (it) Dispositivo per la separazione e l'immagazzinamento
NO20000275D0 (no) Alfs slipsholder
SE9702595D0 (sv) new therapeutic use

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130903

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16